Surrogate end points, skepticism, and the CAST study

Annals of Pharmacotherapy

Volumn 36, Issue 1, 2002, Pages 170-171

  Thompson, Dennis F ^a  

^a SOUTHWESTERN OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DRUG;

DRUG EFFECT; EDITORIAL; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERTENSION; MORTALITY; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME;

EID: 0036140559     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A156     Document Type: Editorial

References (12)

1. Are surrogate markers adequate to assess cardiovascular disease drugs?
2. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
3. Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease
4. Surrogate end points in clinical trials: Are we being misled?
5. Surrogate markers and clinical pharmacology
6. Surrogates, semantics, and sensible public policy
7. What have we learned from the calcium channel blocker controversy?
8. Should new drugs be used without outcome data? Implications of ALLHAT and ELITE II
9. The cardiac arrhythmia suppression trial: Implications for antiarrhythmic drug development
10. Results of the CAST...what did we catch?
11. Antiarrhythmic therapy: Reminders from CAST
12. Loss of skepticism in medical education